JP7221861B2 - オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 - Google Patents

オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 Download PDF

Info

Publication number
JP7221861B2
JP7221861B2 JP2019511749A JP2019511749A JP7221861B2 JP 7221861 B2 JP7221861 B2 JP 7221861B2 JP 2019511749 A JP2019511749 A JP 2019511749A JP 2019511749 A JP2019511749 A JP 2019511749A JP 7221861 B2 JP7221861 B2 JP 7221861B2
Authority
JP
Japan
Prior art keywords
alkyl
fluorophenyl
methyl
hydroxy
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532033A5 (https=
JP2019532033A (ja
Inventor
ジェーン，ラーマ
クリストファー コースター，デニス
アール マニング，ジェームス
マークス，ヴァネッサ
プーン，ダニエル
クリフォード サットン，ジェームス
アール． タフト，ベンジャミン
ワン，リフェン
イフル，アレガヘン
シャオ，キアン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019532033A publication Critical patent/JP2019532033A/ja
Publication of JP2019532033A5 publication Critical patent/JP2019532033A5/ja
Priority to JP2022186394A priority Critical patent/JP2023027102A/ja
Application granted granted Critical
Publication of JP7221861B2 publication Critical patent/JP7221861B2/ja
Priority to JP2025009843A priority patent/JP2025081322A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019511749A 2016-08-29 2017-08-25 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 Active JP7221861B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186394A JP2023027102A (ja) 2016-08-29 2022-11-22 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JP2025009843A JP2025081322A (ja) 2016-08-29 2025-01-23 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380712P 2016-08-29 2016-08-29
US62/380,712 2016-08-29
PCT/IB2017/055137 WO2018042303A1 (en) 2016-08-29 2017-08-25 Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186394A Division JP2023027102A (ja) 2016-08-29 2022-11-22 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物

Publications (3)

Publication Number Publication Date
JP2019532033A JP2019532033A (ja) 2019-11-07
JP2019532033A5 JP2019532033A5 (https=) 2020-10-01
JP7221861B2 true JP7221861B2 (ja) 2023-02-14

Family

ID=59923494

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019511749A Active JP7221861B2 (ja) 2016-08-29 2017-08-25 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JP2022186394A Withdrawn JP2023027102A (ja) 2016-08-29 2022-11-22 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JP2025009843A Pending JP2025081322A (ja) 2016-08-29 2025-01-23 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186394A Withdrawn JP2023027102A (ja) 2016-08-29 2022-11-22 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JP2025009843A Pending JP2025081322A (ja) 2016-08-29 2025-01-23 オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物

Country Status (20)

Country Link
US (4) US10160764B2 (https=)
EP (4) EP3504214B1 (https=)
JP (3) JP7221861B2 (https=)
CN (2) CN113683614B (https=)
AR (1) AR109438A1 (https=)
CA (1) CA3035302A1 (https=)
DK (1) DK4356969T3 (https=)
ES (3) ES3042460T3 (https=)
FI (1) FI4356969T3 (https=)
HR (1) HRP20250885T1 (https=)
HU (1) HUE072776T2 (https=)
JO (1) JOP20170169A1 (https=)
LT (1) LT4356969T (https=)
MX (1) MX383124B (https=)
PL (3) PL3848372T3 (https=)
PT (3) PT3504214T (https=)
SI (3) SI3848372T1 (https=)
TW (3) TWI803467B (https=)
UY (2) UY37378A (https=)
WO (1) WO2018042303A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377396B (es) * 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11247993B2 (en) 2018-01-17 2022-02-15 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
CN118878544A (zh) * 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
CN108440564B (zh) * 2018-04-11 2019-08-06 安帝康（无锡）生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药
US11312727B1 (en) 2018-10-10 2022-04-26 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
WO2021129602A1 (zh) * 2019-12-23 2021-07-01 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022105669A1 (zh) * 2020-11-17 2022-05-27 南京明德新药研发有限公司 含Se大环类化合物
EP4707279A1 (en) * 2023-05-02 2026-03-11 Albius Sciences Beta Pte. Ltd. Substituted tricyclic heterocyclic compound as pharmaceutical for treatment or prevention of covid-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147068A1 (ja) 2009-06-15 2010-12-23 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2012039414A1 (ja) 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
WO2013054862A1 (ja) 2011-10-12 2013-04-18 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2225112A (en) 1938-07-09 1940-12-17 Wright Aeronautical Corp Air cleaner
GB8501542D0 (en) 1985-01-22 1985-02-20 Erba Farmitalia 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives
AUPM354694A0 (en) 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
FR2901795A1 (fr) 2006-05-30 2007-12-07 Fourtillan Snc Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique
CN102203100B (zh) 2008-10-31 2014-08-27 盐野义制药株式会社 具有邻苯二酚基团的头孢菌素
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
RU2012131124A (ru) 2009-12-23 2014-01-27 Элан Фармасьютикалз, Инк. Птеридиноны как ингибиторы polo-подобных киназ
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
JP6089108B2 (ja) 2012-09-20 2017-03-01 セルトリオン， インク． ドラスタチン１０誘導体、その製造方法およびそれを含む抗癌剤組成物
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
US10098913B2 (en) 2013-09-11 2018-10-16 University Of Southern California Composition of stem cells having highly expressed FAS ligand
SI3030549T1 (sl) 2013-09-12 2019-08-30 Janssen Biopharma, Inc. Spojine piridazinona in njihove uporabe
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
US10183945B2 (en) 2016-03-10 2019-01-22 Alios Biopharma, Inc. Method of preparing AZA-pyridone compounds
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP2019059697A (ja) * 2017-09-28 2019-04-18 塩野義製薬株式会社 置換された多環性ピリダジン誘導体およびそのプロドラッグ
US11247993B2 (en) 2018-01-17 2022-02-15 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
CN110041327B (zh) 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN118878544A (zh) 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
JP7282546B2 (ja) 2018-02-28 2023-05-29 日本たばこ産業株式会社 ４－メチルジヒドロピリミジノン化合物及びその医薬用途
JP7089596B2 (ja) 2018-02-28 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体
PE20210447A1 (es) 2018-02-28 2021-03-08 Japan Tobacco Inc Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147068A1 (ja) 2009-06-15 2010-12-23 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2012039414A1 (ja) 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
WO2013054862A1 (ja) 2011-10-12 2013-04-18 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof

Also Published As

Publication number Publication date
CN113683614B (zh) 2024-11-08
JP2025081322A (ja) 2025-05-27
PT3504214T (pt) 2021-03-04
LT4356969T (lt) 2025-09-10
US20220041610A1 (en) 2022-02-10
EP3848372A1 (en) 2021-07-14
TW202342482A (zh) 2023-11-01
SI4356969T1 (sl) 2025-10-30
MX383124B (es) 2025-03-13
TWI803467B (zh) 2023-06-01
HRP20250885T1 (hr) 2025-09-26
CN109863151B (zh) 2021-09-10
CA3035302A1 (en) 2018-03-08
US10160764B2 (en) 2018-12-25
DK4356969T3 (da) 2025-08-18
EP3504214B1 (en) 2020-12-02
TWI869757B (zh) 2025-01-11
UY37378A (es) 2018-03-23
JOP20170169A1 (ar) 2019-01-30
CN113683614A (zh) 2021-11-23
US20180057501A1 (en) 2018-03-01
MX2019002438A (es) 2019-07-08
TW202517646A (zh) 2025-05-01
ES2974494T3 (es) 2024-06-27
ES3042460T3 (en) 2025-11-20
PL3848372T3 (pl) 2024-04-22
US11912715B2 (en) 2024-02-27
US20250011334A1 (en) 2025-01-09
HUE072776T2 (hu) 2025-12-28
EP4356969A2 (en) 2024-04-24
EP4356969A3 (en) 2024-05-22
AR109438A1 (es) 2018-11-28
ES2859510T3 (es) 2021-10-04
EP4640279A2 (en) 2025-10-29
UY40872A (es) 2024-09-13
EP3504214A1 (en) 2019-07-03
PL4356969T3 (pl) 2025-10-20
CN109863151A (zh) 2019-06-07
SI3504214T1 (sl) 2021-04-30
PL3504214T3 (pl) 2021-07-19
EP4640279A3 (en) 2025-12-24
JP2023027102A (ja) 2023-03-01
TW201811800A (zh) 2018-04-01
WO2018042303A1 (en) 2018-03-08
JP2019532033A (ja) 2019-11-07
FI4356969T3 (fi) 2025-08-15
EP4356969B1 (en) 2025-07-09
EP3848372B1 (en) 2023-12-20
PT3848372T (pt) 2024-03-22
US11098051B2 (en) 2021-08-24
US20200123167A1 (en) 2020-04-23
SI3848372T1 (sl) 2024-04-30
PT4356969T (pt) 2025-10-02

Similar Documents

Publication Publication Date Title
JP7221861B2 (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
JP2026034569A (ja) インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物
HK40110231A (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40055239B (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40055239A (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40009860B (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40009860A (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40009791A (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40042824B (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
HK40042824A (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
HK40009791B (zh) 用於治疗正粘病毒感染的稠合三环哒嗪酮化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230202

R150 Certificate of patent or registration of utility model

Ref document number: 7221861

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250